José Ramón
González Porras
Profesor Asociado CC. Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (10)
2024
-
ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy
Blood, Vol. 143, Núm. 18, pp. 1807-1815
-
Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction
Cellular and Molecular Life Sciences, Vol. 81, Núm. 1
2021
-
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients
Blood Cells, Molecules, and Diseases, Vol. 86
-
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)
Scientific Reports
-
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain
British Journal of Haematology, Vol. 194, Núm. 3, pp. 537-541
2019
2017
-
Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®
Quality of Life Research, Vol. 26, Núm. 3, pp. 767-778
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116